PARP inhibitors for ALS? Penn researchers post promising finds in brain disease
As a cancer drug, PARP inhibitors have inspired blockbuster projections for drugmakers like AstraZeneca and Pfizer. What if they can also treat brain diseases?
A team of researchers at the University of Pennsylvania are trying to answer that question, having found that aside from stopping tumor cells from repairing damaged DNA, PARP inhibitors can also reduce the amount of a harmful structure that’s associated with amyotrophic lateral sclerosis — known as ALS or Lou Gehrig’s disease — and some forms of frontotemporal degeneration (FTD).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
